Hangzhou Alltest Biotech Co. Ltd. A (688606) - Net Assets

Latest as of March 2026: CN¥3.88 Billion CNY ≈ $568.10 Million USD

Based on the latest financial reports, Hangzhou Alltest Biotech Co. Ltd. A (688606) has net assets worth CN¥3.88 Billion CNY (≈ $568.10 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.11 Billion ≈ $601.28 Million USD) and total liabilities (CN¥226.79 Million ≈ $33.19 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. For live market cap and overall valuation, see Hangzhou Alltest Biotech Co. Ltd. A (688606) total market value.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥3.88 Billion
% of Total Assets	94.48%
Annual Growth Rate	73.78%
5-Year Change	20.55%
10-Year Change	N/A
Growth Volatility	138.27

Hangzhou Alltest Biotech Co. Ltd. A - Net Assets Trend (2016–2025)

This chart illustrates how Hangzhou Alltest Biotech Co. Ltd. A's net assets have evolved over time, based on quarterly financial data.

Annual Net Assets for Hangzhou Alltest Biotech Co. Ltd. A (2016–2025)

The table below shows the annual net assets of Hangzhou Alltest Biotech Co. Ltd. A from 2016 to 2025. See 688606 equity financing ratio to measure how much of total assets are equity-financed.

Year	Net Assets	Change
2025-12-31	CN¥3.95 Billion ≈ $577.47 Million	+1.62%
2024-12-31	CN¥3.88 Billion ≈ $568.27 Million	+1.35%
2023-12-31	CN¥3.83 Billion ≈ $560.68 Million	-8.14%
2022-12-31	CN¥4.17 Billion ≈ $610.34 Million	+27.41%
2021-12-31	CN¥3.27 Billion ≈ $479.04 Million	+236.56%
2020-12-31	CN¥972.66 Million ≈ $142.33 Million	+231.74%
2019-12-31	CN¥293.20 Million ≈ $42.90 Million	+36.31%
2018-12-31	CN¥215.10 Million ≈ $31.48 Million	+55.18%
2017-12-31	CN¥138.61 Million ≈ $20.28 Million	+407.45%
2016-12-31	CN¥27.32 Million ≈ $4.00 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Hangzhou Alltest Biotech Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 17465.5% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥1.94 Billion	49.06%
Other Components	CN¥2.01 Billion	50.94%
Total Equity	CN¥3.95 Billion	100.00%

Hangzhou Alltest Biotech Co. Ltd. A Competitors by Market Cap

The table below lists competitors of Hangzhou Alltest Biotech Co. Ltd. A ranked by their market capitalization.

Company	Market Cap
Midi Utama Indonesia Tbk JK:MIDI	$556.41 Million
Sichuan Xichang Electric Power Co Ltd SHG:600505	$556.42 Million
MOIL Limited NSE:MOIL	$556.43 Million
TELUS International TO:TIXT	$556.44 Million
PRINC.PR.EQ.HLDGS EO-001 F:PEYA	$556.21 Million
Zhejiang Tengen Electrics Co Ltd SHG:605066	$556.17 Million
Diversified Royalty Corp TO:DIV	$556.11 Million
Ningbo Shenglong Automotive Powertrain System Co Ltd SHG:603178	$555.93 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hangzhou Alltest Biotech Co. Ltd. A's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 3,883,641,163 to 3,946,690,966, a change of 63,049,803 (1.6%).
Net income of 218,280,100 contributed positively to equity growth.
Dividend payments of 195,109,725 reduced retained earnings.
Other comprehensive income decreased equity by 317,662,486.
Other factors increased equity by 357,541,914.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥218.28 Million	+5.53%
Dividends Paid	CN¥195.11 Million	-4.94%
Other Comprehensive Income	CN¥-317.66 Million	-8.05%
Other Changes	CN¥357.54 Million	+9.06%
Total Change	CN¥-	1.62%

Book Value vs Market Value Analysis

This analysis compares Hangzhou Alltest Biotech Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.96x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 32.58x to 0.96x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	CN¥1.47	CN¥47.96	x
2017-12-31	CN¥2.41	CN¥47.96	x
2018-12-31	CN¥3.68	CN¥47.96	x
2019-12-31	CN¥4.90	CN¥47.96	x
2020-12-31	CN¥16.27	CN¥47.96	x
2021-12-31	CN¥43.77	CN¥47.96	x
2022-12-31	CN¥52.57	CN¥47.96	x
2023-12-31	CN¥48.32	CN¥47.96	x
2024-12-31	CN¥49.05	CN¥47.96	x
2025-12-31	CN¥49.72	CN¥47.96	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hangzhou Alltest Biotech Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 5.53%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 23.95%
• Asset Turnover: 0.21x
• Equity Multiplier: 1.07x
Recent ROE (5.53%) is below the historical average (27.33%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2016	56.00%	20.09%	1.27x	2.20x	CN¥12.49 Million
2017	24.65%	26.34%	0.68x	1.37x	CN¥20.31 Million
2018	26.23%	30.63%	0.72x	1.18x	CN¥34.92 Million
2019	26.75%	32.49%	0.73x	1.13x	CN¥49.10 Million
2020	69.83%	59.81%	0.99x	1.18x	CN¥581.96 Million
2021	23.39%	40.87%	0.47x	1.22x	CN¥438.33 Million
2022	28.44%	34.97%	0.72x	1.13x	CN¥768.27 Million
2023	4.72%	23.93%	0.18x	1.08x	CN¥-202.15 Million
2024	7.79%	34.90%	0.21x	1.08x	CN¥-85.89 Million
2025	5.53%	23.95%	0.21x	1.07x	CN¥-176.39 Million

Industry Comparison

This section compares Hangzhou Alltest Biotech Co. Ltd. A's net assets metrics with peer companies in the Medical Instruments & Supplies industry.

Industry Context

Industry: Medical Instruments & Supplies
Average net assets among peers: $1,388,020,891
Average return on equity (ROE) among peers: 12.43%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Hangzhou Alltest Biotech Co. Ltd. A (688606)	CN¥3.88 Billion	56.00%	0.06x	$556.40 Million
Beijing Centergate Technologies Holding Co Ltd (000931)	$1.74 Billion	2.80%	1.18x	$560.95 Million
Blue Sail Medical Co Ltd (002382)	$1.43 Billion	14.06%	0.29x	$868.43 Million
Andon Health Co Ltd (002432)	$119.28 Million	36.81%	0.27x	$4.82 Billion
Allmed Medical Products Co Ltd Class A (002950)	$2.75 Billion	15.67%	0.82x	$862.73 Million
Guangzhou Improve Med Instrument (300030)	$1.03 Billion	1.80%	0.77x	$309.02 Million
QITIAN Technology Group Co Ltd (300061)	$2.47 Billion	-32.17%	0.22x	$608.48 Million
Shanghai Tofflon Science Tech (300171)	$3.69 Billion	12.55%	0.78x	$1.62 Billion
Truking Technology Ltd (300358)	$154.72 Million	34.37%	1.72x	$941.76 Million
Jiangxi Sanxin Medtec Co Ltd (300453)	$207.61 Million	23.43%	0.59x	$755.57 Million
Shenyang Xingqi Pharmaceutical Co Ltd (300573)	$290.70 Million	15.03%	0.44x	$1.43 Billion

About Hangzhou Alltest Biotech Co. Ltd. A

SHG:688606 China Medical Instruments & Supplies

Market Cap

$556.40 Million

CN¥3.80 Billion CNY

Market Cap Rank

#11746 Global

#3329 in China

Share Price

CN¥47.96

Change (1 day)

-2.72%

52-Week Range

CN¥41.00 - CN¥76.17

All Time High

CN¥121.60